10-Q: TriSalus Life Sciences Reports Q1 2025 Financial Results, Revenue Up 42%
Quarterly Report
TriSalus Life Sciences saw a 42% increase in revenue in Q1 2025, driven by increased sales of its TriNav infusion system, but continues to operate at a loss.
Summary
- TriSalus Life Sciences reported a net loss of $10.4 million for the three months ended March 31, 2025.
- Revenue increased by 42% to $9.167 million compared to $6.457 million in the same period last year, driven by increased TriNav sales.
- Cost of goods sold increased by 54% due to higher production volumes.
- Research and development expenses decreased by 43.6% due to reduced clinical trial expenses and headcount-related expenses.
- The company borrowed $10 million under the OrbiMed Credit Agreement after achieving a trailing 12-month Product Revenue Base of $30 million.
- TriSalus entered into a securities purchase agreement in April 2025 to raise $22 million through a private placement.
- The company acknowledges substantial doubt about its ability to continue as a going concern within the next 12 months without additional financing.
- The Conversion Price of Series A Convertible Preferred Stock was reset to $5.277, leading to the conversion of 365,000 shares into 777,829 shares of common stock.
- Effective April 1, 2025, TriNav received a second unique and permanent HCPCS code from CMS, C8004, which has been assigned to APC 5193 (Level 3 Endovascular Procedures).
Sentiment
Score: 5
Explanation: The document presents a mixed picture. While revenue growth is positive, the company's continued losses, going concern warning, and material weaknesses in internal controls raise concerns. The successful private placement provides some reassurance, but the overall outlook is uncertain.
Positives
- Significant revenue growth of 42% year-over-year, indicating increasing market adoption of TriNav.
- Successful draw of $10 million under the OrbiMed Credit Agreement, demonstrating achievement of revenue targets.
- Securing $22 million in gross proceeds through a private placement to bolster financial position.
- Reduction in research and development expenses, potentially improving operational efficiency.
- Receipt of a second unique and permanent HCPCS code from CMS for TriNav, providing reimbursement clarity.
Negatives
- Continued net losses, with a $10.4 million loss reported for Q1 2025.
- Substantial doubt about the company's ability to continue as a going concern without additional financing.
- Increased cost of goods sold, impacting gross margin despite revenue growth.
- Material weaknesses identified in internal control over financial reporting.
Risks
- The company's ability to secure additional financing is uncertain.
- Failure to maintain current TriNav pricing and gross margins could impact profitability.
- Clinical trials for nelitolimod may not be successful or cost-effective.
- FDA approval for nelitolimod is not guaranteed.
- Material weaknesses in internal control over financial reporting could affect the accuracy and timeliness of financial reporting.
Future Outlook
The company expects to continue to incur net losses for the foreseeable future due to investments in R&D and sales and marketing. The company's ability to draw the remaining $15.0 million available under the OrbiMed Credit Agreement if and when needed. The company will need to obtain substantial additional funding in connection with its continuing operations.
Industry Context
The company operates in the oncology-focused medical technology sector, which is characterized by rapid innovation and evolving treatment paradigms. The company's focus on improving therapeutic delivery to solid tumors aligns with broader industry trends in precision medicine and targeted therapies.
Comparison to Industry Standards
- Given the limited financial details, a precise comparison to industry standards is challenging.
- However, medical device companies like Boston Scientific and Medtronic typically invest heavily in R&D (around 10-15% of revenue).
- TriSalus's R&D spending as a percentage of revenue is higher, reflecting its stage of development.
- Gross margins for medical device companies often range from 60-80%, so TriSalus's gross margin of 83.7% is relatively high, but this may not be sustainable.
- Companies like Exact Sciences and Guardant Health, which are also in high-growth phases, often experience significant net losses as they scale their commercial operations.
Stakeholder Impact
- Shareholders face potential dilution from future equity offerings.
- Employees may be affected by cost-cutting measures if financing is not secured.
- Customers (hospitals, clinics, physicians) may benefit from continued innovation and product development.
- Suppliers and creditors face increased risk due to the company's financial instability.
Next Steps
- Continue commercialization efforts for TriNav to drive revenue growth.
- Pursue additional financing to address going concern concerns.
- Remediate material weaknesses in internal control over financial reporting.
- Advance clinical trials for nelitolimod and seek potential pharmaceutical partners.
- Monitor reimbursement landscape for TriNav and adapt pricing strategies as needed.
Key Dates
| Date | Description |
|---|---|
| 2020-01-01 | TriNav introduced to market |
| 2020-07-31 | Date of Asset Purchase Agreement between TriSalus and Dynavax |
| 2021-03-02 | Date of Strategic Collaboration Agreement between TriSalus and MD Anderson Cancer Center |
| 2023-08-10 | Closing date of the merger with MedTech Acquisition Corporation |
| 2023-12-31 | Expiration of transitional pass-through payments (TPT) approval from CMS |
| 2024-01-01 | New Technology Healthcare Common Procedure Coding System (HCPCS) code for TriNav becomes effective |
| 2024-04-30 | Date of OrbiMed Credit Agreement |
| 2025-02-10 | Conversion Price of Series A Convertible Preferred Stock reset to $5.277 |
| 2025-02-18 | Company borrowed the First Delayed Draw Term Loan Commitment resulting in gross proceeds of $10.0 million |
| 2025-02-25 | Effective date of modification and extension of MDACC Agreement payment terms |
| 2025-03-20 | Effective date of First Amendment To Credit Agreement and Registration Rights Agreement |
| 2025-03-31 | Date of waiver to extend the timing for the required audited financial statements to occur on or before April 15, 2025 |
| 2025-03-31 | End of Q1 2025 reporting period |
| 2025-04-01 | Effective date of second unique and permanent HCPCS code from CMS, C8004 |
| 2025-04-30 | Effective date of Second Amendment To Credit Agreement |
| 2025-04-30 | Date of securities purchase agreement |
| 2025-05-02 | Private Placement closed |
| 2025-05-09 | Date of report |
| 2025-06-30 | Expiration date of the First Delayed Draw Term Loan Commitment |
| 2025-10-31 | Evidence that on or prior to October 31, 2025, Global Biolink Ltd has been dissolved |
| 2025-12-31 | Expiration date of the Second Delayed Draw Term Loan Commitment |
Keywords
TriSalus, TriNav, nelitolimod, revenue, clinical trials, OrbiMed, financing, HCPCS, preferred stock, warrants
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.